|Contact:||Dr. Laurent Levy, CEO||Phone:||33 (0) 1 40 26 04 70|
|E-mail:||Address:||60 Rue de Wattignies 75012 Paris|
Nanobiotix is focused on the development of nanoparticle based methods of treating cancer to replace current radiotherapy methods while minimizing damage to healthy tissue.
Nanomedicine Related Products
Nanobiotix has completed precinical testing of NanoXray™. NanoXray™ is a method of treating cancer tumors in which x-rays are focused on a tumor in which nanoparticles, that Nanobiotix has named nbtxr3, have been concentrated. The nbtxr3 nanoparticles release electrons when illuminated by the x-rays, which generates free radicals and causes the destruction of the tumor.
Nanobiotix is developing two other nanoparticle based therapies:
Product Development Affiliations
Nanobiotix is collaborating with a group of industry partners, university medical centers, and academic institutions in a project called "SonoDrugs". The consortium will develop nanoparticulate based drug delivery using focused ultrasound to control the location of the drug release .
Nanobiotix and BiotechCorp are collaborating on developing point-of-care (P-O-C) diagnostics and drug delivery systems for tropical diseases, such as malaria.
Subsidiaries or Parent Company
Primary Investors or Funding Source
Private company primarily funded by venture capital firms including Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes